Jennifer Ho1, Paul A Tambyah, David L Paterson. 1. National University Hospital Singapore, Department of Infectious Diseases, Singapore, Singapore. jho@gmp.usyd.edu.au
Abstract
PURPOSE OF REVIEW: Multiresistant Gram-negative infections are an increasing problem in hospitals and healthcare facilities worldwide. While much attention has been paid to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus lately, the importance of Gram-negative nosocomial infections has also been recognized globally. RECENT FINDINGS: Recent reports have described the spread of carbapenemase-producing Klebsiella pneumoniae across North America. In addition, many strains of Pseudomonas and Acinetobacter in Asia are resistant to all known antibiotics. The global epidemiology of multiresistant Gram-negative pathogens seems to vary by continent. There are very few existing agents which can be used for these pathogens and there are limited options on the horizon. This limited therapeutic armamentarium has been an impetus for novel approaches including combination therapies and increased attention to infection control and prevention efforts. SUMMARY: Clinicians need to be aware of the rising problem of resistance in nosocomial and community-acquired Gram-negative pathogens. Novel agents are urgently needed to combat these infections and innovative infection control strategies need to be devised to protect our vulnerable patients.
PURPOSE OF REVIEW: Multiresistant Gram-negative infections are an increasing problem in hospitals and healthcare facilities worldwide. While much attention has been paid to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus lately, the importance of Gram-negative nosocomial infections has also been recognized globally. RECENT FINDINGS: Recent reports have described the spread of carbapenemase-producing Klebsiella pneumoniae across North America. In addition, many strains of Pseudomonas and Acinetobacter in Asia are resistant to all known antibiotics. The global epidemiology of multiresistant Gram-negative pathogens seems to vary by continent. There are very few existing agents which can be used for these pathogens and there are limited options on the horizon. This limited therapeutic armamentarium has been an impetus for novel approaches including combination therapies and increased attention to infection control and prevention efforts. SUMMARY: Clinicians need to be aware of the rising problem of resistance in nosocomial and community-acquired Gram-negative pathogens. Novel agents are urgently needed to combat these infections and innovative infection control strategies need to be devised to protect our vulnerable patients.
Authors: Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham Journal: Antimicrob Agents Chemother Date: 2012-04-09 Impact factor: 5.191
Authors: Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191
Authors: Jolanta Krucinska; Eric Falcone; Heidi Erlandsen; Akram Hazeen; Michael N Lombardo; Alexavier Estrada; Victoria L Robinson; Amy C Anderson; Dennis L Wright Journal: Biochemistry Date: 2019-02-15 Impact factor: 3.162
Authors: Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191
Authors: Shalini Narayanan; Joyanta K Modak; Catherine S Ryan; Jose Garcia-Bustos; John K Davies; Anna Roujeinikova Journal: Antimicrob Agents Chemother Date: 2014-03-03 Impact factor: 5.191
Authors: Anthony D Harris; Lisa Pineles; Beverly Belton; J Kristie Johnson; Michelle Shardell; Mark Loeb; Robin Newhouse; Louise Dembry; Barbara Braun; Eli N Perencevich; Kendall K Hall; Daniel J Morgan; Syed K Shahryar; Connie S Price; Joseph J Gadbaw; Marci Drees; Daniel H Kett; L Silvia Muñoz-Price; Jesse T Jacob; Loreen A Herwaldt; Carol A Sulis; Deborah S Yokoe; Lisa Maragakis; Matthew E Lissauer; Marcus J Zervos; David K Warren; Robin L Carver; Deverick J Anderson; David P Calfee; Jason E Bowling; Nasia Safdar Journal: JAMA Date: 2013-10-16 Impact factor: 56.272